244 related articles for article (PubMed ID: 21837489)
1. [Renal cell carcinoma: what is new in 2010?].
Tsaur I; Haferkamp A
Urologe A; 2011 Sep; 50 Suppl 1():216-8. PubMed ID: 21837489
[TBL] [Abstract][Full Text] [Related]
2. [Renal cell carcinoma].
Fornara P; Hoda MR
Urologe A; 2011 Sep; 50 Suppl 1():219-22. PubMed ID: 21837488
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant therapy in renal cell carcinoma: is resection still solely enough?
Gharib KE
Future Oncol; 2021 Feb; 17(6):633-636. PubMed ID: 33305597
[No Abstract] [Full Text] [Related]
4. The changing landscape of systemic therapy in metastatic renal cell carcinoma: an update.
Gurram S; Al Harthy M; Ball MW
Discov Med; 2020; 29(158):191-199. PubMed ID: 33007194
[TBL] [Abstract][Full Text] [Related]
5. Complete responses in advanced renal cell carcinoma: utopia or real chance?
Verzoni E; Garanzini E; Procopio G
Clin Exp Nephrol; 2013 Feb; 17(1):151-2. PubMed ID: 23292180
[No Abstract] [Full Text] [Related]
6. The impact of cytoreductive nephrectomy on survival outcomes in patients treated with tyrosine kinase inhibitors for metastatic renal cell carcinoma in a real-world cohort.
Janisch F; Hillemacher T; Fuehner C; D'Andrea D; Meyer CP; Klotzbücher T; Kienapfel C; Vetterlein MW; Kimura S; Abufaraj M; Dahlem R; Shariat SF; Fisch M; Rink M
Urol Oncol; 2020 Sep; 38(9):739.e9-739.e15. PubMed ID: 32576526
[TBL] [Abstract][Full Text] [Related]
7. [Are immunotherapy and chemotherapy in metastatic renal cell cancer out?].
Schmitz-Dräger BJ
Urologe A; 1992 Jul; 31(4):213-4. PubMed ID: 1514204
[No Abstract] [Full Text] [Related]
8. Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitors.
Santoni M; Conti A; Partelli S; Porta C; Sternberg CN; Procopio G; Bracarda S; Basso U; De Giorgi U; Derosa L; Rizzo M; Ortega C; Massari F; Iacovelli R; Milella M; Di Lorenzo G; Buti S; Cerbone L; Burattini L; Montironi R; Santini D; Falconi M; Cascinu S
Ann Surg Oncol; 2015; 22(6):2094-100. PubMed ID: 25472645
[TBL] [Abstract][Full Text] [Related]
9. Integration of surgery and systemic therapy for renal cell carcinoma.
Kenney PA; Wood CG
Urol Clin North Am; 2012 May; 39(2):211-31, vii. PubMed ID: 22487764
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of nephrectomy in metastatic renal cell carcinoma treated with systemic cytokine or targeted therapy: A 16-year retrospective analysis.
Kim SH; Jeong KC; Joung JY; Seo HK; Lee KH; Chung J
Sci Rep; 2018 Feb; 8(1):2974. PubMed ID: 29445167
[TBL] [Abstract][Full Text] [Related]
11. Systemic Treatments for Metastatic Renal Cell Carcinoma: 10-Year Experience of Immunotherapy and Targeted Therapy.
Kim SH; Park WS; Kim SH; Joung JY; Seo HK; Lee KH; Chung J
Cancer Res Treat; 2016 Jul; 48(3):1092-101. PubMed ID: 26875203
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors and molecular markers for renal cell carcinoma.
Bui MH; Zisman A; Pantuck AJ; Han KR; Wieder J; Belldegrun AS
Expert Rev Anticancer Ther; 2001 Dec; 1(4):565-75. PubMed ID: 12113089
[TBL] [Abstract][Full Text] [Related]
13. Renal cell carcinoma in children and adolescents.
Spreafico F; Collini P; Terenziani M; Marchianò A; Piva L
Expert Rev Anticancer Ther; 2010 Dec; 10(12):1967-78. PubMed ID: 21110762
[TBL] [Abstract][Full Text] [Related]
14. Managing the complex journey of renal cell carcinoma.
Amen K
ONS Connect; 2007; 22(8 Suppl):53-4. PubMed ID: 17824565
[No Abstract] [Full Text] [Related]
15. Prognostic prediction in patients with metastatic renal cell carcinoma treated with sorafenib based on expression levels of potential molecular markers in radical nephrectomy specimens.
Kusuda Y; Miyake H; Behnsawy HM; Fukuhara T; Inoue TA; Fujisawa M
Urol Oncol; 2013 Jan; 31(1):42-50. PubMed ID: 21396851
[TBL] [Abstract][Full Text] [Related]
16. The evolving role of cytoreductive surgery for metastatic renal cell carcinoma.
Chaudhary UB; Hull GW
Oncology (Williston Park); 2003 May; 17(5):701-5; discussion 705-6, 711-2. PubMed ID: 12800795
[TBL] [Abstract][Full Text] [Related]
17. Expression level of vascular endothelial growth factor receptor-2 in radical nephrectomy specimens as a prognostic predictor in patients with metastatic renal cell carcinoma treated with sunitinib.
Terakawa T; Miyake H; Kusuda Y; Fujisawa M
Urol Oncol; 2013 May; 31(4):493-8. PubMed ID: 21478036
[TBL] [Abstract][Full Text] [Related]
18. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma.
Vasselli JR; Yang JC; Linehan WM; White DE; Rosenberg SA; Walther MM
J Urol; 2001 Jul; 166(1):68-72. PubMed ID: 11435825
[TBL] [Abstract][Full Text] [Related]
19. The Impact of Local Intervention Combined with Targeted Therapy on Metastatic Renal Cell Carcinoma.
Li JR; Ou YC; Yang CK; Wang SS; Chen CS; Ho HC; Cheng CL; Yang CR; Chen CC; Wang SC; Lin CY; Hung SC; Hsu CY; Chiu KY
Anticancer Res; 2018 Sep; 38(9):5339-5345. PubMed ID: 30194186
[TBL] [Abstract][Full Text] [Related]
20. Renal cell carcinoma: what the surgeon and treating physician need to know.
Chapin BF; Delacroix SE; Wood CG
AJR Am J Roentgenol; 2011 Jun; 196(6):1255-62. PubMed ID: 21606286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
